cabozantinib


( Last Updated : June 6, 2022)
Generic Name:
cabozantinib
Project Status:
Active
Therapeutic Area:
Differentiated thyroid carcinoma
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cabometyx
Project Line:
Reimbursement Review
Project Number:
PC0287-000
Call for patient/clinician input closed:
Tumour Type:
Head and Neck
NOC Status at Filing:
Pre NOC

Details

Manufacturer Requested Reimbursement Criteria1:
Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Head and Neck
Indications:
Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open29-Mar-22
Call for patient/clinician input closed20-May-22
Clarification:

- Patient input submission received from Canadian Cancer Society and Thyroid Cancer Canada

Submission received27-Apr-22
Submission accepted
Review initiated12-May-22
Draft CADTH review report(s) provided to sponsor for comment27-Jul-22
Deadline for sponsors comments08-Aug-22
CADTH review report(s) and responses to comments provided to sponsor01-Sep-22
Expert committee meeting (initial)14-Sep-22
Draft recommendation issued to sponsorSeptember 26, 2022
To
September 28, 2022
Draft recommendation posted for stakeholder feedback06-Oct-22
End of feedback period21-Oct-22